GP40081 + NovoMix 30

Phase 3UNKNOWN
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 2

Conditions

Diabetes Mellitus, Type 2, Diabetes Mellitus

Trial Timeline

Jan 20, 2020 → Dec 25, 2020

About GP40081 + NovoMix 30

GP40081 + NovoMix 30 is a phase 3 stage product being developed by GEROPHARM for Diabetes Mellitus, Type 2. The current trial status is unknown. This product is registered under clinical trial identifier NCT04226105. Target conditions include Diabetes Mellitus, Type 2, Diabetes Mellitus.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04226105Phase 3UNKNOWN